Lupin Acquires 5 Brands From Menarini

The five major brands cover strategic therapy areas such as gastroenterology, urology and anti-infectives. Additionally, the company is in charge of the associated trademark rights of these brands.

Global pharmaceutical giant Lupin Limited (Lupin) has entered into an agreement to acquire five legacy brands from Menarini (A. Menarini India Private Limited and A. Menarini AsiaPacific Holdings Pte. Ltd).

The Mumbai-based Pharma has been exclusively marketing these brands in the Indian market since July 2021 through a distribution and promotion agreement with Menarini India. 

With the acquisition of these legacy brands from Menarini, Lupin aims to expand its presence in the Indian market by further enhancing and diversifying its portfolio.

The five major brands including Piclin (Picosulphate Sodium), Menoctyl (Otilonium Bromide), Sucramal O (Sucralfate + Oxetacaine), Pyridium (Phenazopyridine) and Distaclor (Cefaclor) cover strategic therapy areas such as gastroenterology, urology and anti-infectives. 

Additionally, the company is in charge of the associated trademark rights of these brands.

Sharing his views, Girisan Kariangal, MD, Menarini India, said, 'œLupin has been successfully marketing the scope brands for Menarini since 2021, which has been a testament to our evolved collaboration. I am happy that Lupin will now carry forward its legacy with full trademark ownership. For Menarini, this transaction further signals our continued commitment to nurture and expand our Dermatology and Aesthetics portfolio and business. Menarini is a top 10 multinational company in this therapeutic area in India and has witnessed strong organic and inorganic growth.'

Founded in 1968, the Indian multinational pharmaceutical company offers a diverse portfolio of branded and generic formulations, biotechnology products, and APIs. Lupin serves over 100 markets spanning the US, India, South Africa, Asia Pacific (APAC), Latin America (LATAM), Europe, and the Middle East. Lupin's key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.

Just days back, Lupin collaborated with Mark Cuban's Cost Plus Drug Company and COPD Foundation to make Tiotropium Bromide Inhalation Powder, 18 mcg/capsule, more accessible to COPD patients in the US.

In another development, the Mumbai-based pharma launched a digital heart failure clinic in India, which is the first ever in the country. With this initiative. Lupin aims to provide comprehensive care to patients suffering from heart failure, with a focus on remote monitoring and disease management.

While the Italian pharmaceutical company Menarini develops pharmacological solutions for cardiovascular diseases, oncology, pain/inflammation, asthma and anti-infectives. The company has three divisions-Menarini Ricerche, Menarini Biotech, and Menarini Diagnostics.

Located in Ahmedabad, Menarini India aims to provide high-quality healthcare products to meet the evolving clinical needs of patients and healthcare professionals. Currently, it is among the top 10 multinational companies in the therapeutic area in India.